Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Non-Current Deffered Revenue: 2024

Historic Non-Current Deffered Revenue for Collegium Pharmaceutical (COLL) over the last 1 years, with Dec 2024 value amounting to $10.0 million.

  • Collegium Pharmaceutical's Non-Current Deffered Revenue fell 7.22% to $9.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.3 million, marking a year-over-year decrease of 7.22%. This contributed to the annual value of $10.0 million for FY2024, which is N/A change from last year.
  • According to the latest figures from FY2024, Collegium Pharmaceutical's Non-Current Deffered Revenue is $10.0 million.
  • Collegium Pharmaceutical's Non-Current Deffered Revenue's 5-year high stood at $10.0 million during FY2024, with a 5-year trough of $10.0 million in FY2024.
  • Its 1-year average for Non-Current Deffered Revenue is $10.0 million, with a median of $10.0 million in 2024.